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Antimicrobial resistance (AMR) is a fast-evolving global public 
health crisis. The UK Chief Medical Officer calls it a catastrophe 
ranking with terrorism and climate change.1 Its consequences are an 
unenviable return to a pre-antibiotic dawn, rendering many routine 
infections untreatable,2 and putting much major surgery, organ 
transplantation and cancer chemotherapy out of safe reach.3 
The World Health Organization (WHO) has called for 
implementation of programs to contain AMR (Box 1). These 
initiatives are supported by several multi-national4 and national5-8 
surveillance and stewardship programs. Some have shown decreasing 
antibiotic use and consequent decreased resistance. Australia has 
been part of this, although we still have no nationally coordinated 
surveillance system for antimicrobial use or resistance. 
What has happened in Australia?
Antibiotic resistance appeared on the Australian government agenda 
in the early 1980s. The evolution of different bodies and responses has 
been complicated (Table 1). These can be classified into: resistance 
surveillance; regulatory measures; and infection prevention and 
control – the latter obviously based on the premise that reducing 
infection reduces the need for antibiotics. As the table shows, the 
focus is on hospital care (where the effects of antimicrobial resistance 
is most keenly felt), although it is actually the community where the 
greatest tonnage of antibiotics are prescribed (often inappropriately – 
especially for acute respiratory infections). Health education body NPS 
MedicineWise is currently focused on this community gap. 
What needs to happen?
First and foremost, a national over-arching body engaged in the 
process is very important. It looks as if this is happening. In March 
2013, a high level steering group was established consisting of 
the chief health officer; the chief veterinary officer; heads of the 
Department of Health and Ageing (DoHA) and the Department of 
Agriculture, Fisheries and Forestry (DAFF); and the CEO of the 
Australian Commission on Safety and Quality in Health Care. This 
group supplements the Antimicrobial Resistance Standing Committee9 
established in 2012 to provide technical advice to DoHA on resistance 
issues. 
What can they do? Perhaps they should consider important – if 
draconian – steps to preserve our antibiotics. Following on the 
Australian success of the sequestration of quinolones,19 more 
antibiotics could be put aside for use only with specific patients, 
with obstructions to access by generalists and junior hospital doctors 
(such as the Authority to Prescribe), although this approach would be 
highly unpopular with prescribers. On the surveillance side, we need 
sentinel general practices (already established in many parts of the 
world10 including Australia11) to participate in a structured and ongoing 
surveillance program across the country to gain a better understanding 
of pathogens and their antibiotic susceptibilities. Compilation and 
analysis of the vast volume of information from public and private 
microbiology laboratories would be of immense value. 
Other research questions include ways of not just limiting the spread 
of infection, but the spread of resistance genes themselves (as they have 
the capacity to jump species and between pathogenic and commensal 
organisms). We need a better understanding of the contribution of 
hospitals and the community to resistance, and the extent to which 
primary care prescribers can reduce their antibiotic prescribing, and 
whether that will affect resistance generation. To be successful, these 
initiatives may need to access incentives such as the Practice Incentives 
Program, or even to address more fundamental factors of our health 
care system, such as the fee-for-service environment and the right to 
independent practice. Otherwise we are asking too much of hospital 
antimicrobial stewardship programs and their nascent community 
equivalents, such as NPS MedicineWise.
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Table 1: Some Australian activities in response to antimicrobial resistance.
Milestone Brief elaboration
Resistance Surveillance
Working Party on Antibiotics (WPA) established by NHMRC (1980s) To address resistance arising in food animals and spreading to humans.13 
WPA evolved into the Joint Expert Committee on Antibiotic Resistance 
(JETACAR), reporting in 1999
Proposed antibiotic-resistance management program simultaneously focused 
on human and animal use of antibiotics – Made 22 recommendations, relating to 
regulation, monitoring and surveillance, infection prevention strategies, education and 
research.14
Commonwealth Response to JETACAR (2000). EAGAR16 and CIJIG17 
later reported, but momentum was lost
Largely supported recommendations15 – Proposed establishment of Expert Advisory 
Group on Antimicrobial Resistance (EAGAR) in 2001 and a Commonwealth inter-
departmental JETACAR Implementation Group (CIJIG, 2000).
Strategy for Antimicrobial Resistance Surveillance in Australia (2003) Strategy to address both JETACAR recommendations for monitoring and surveillance 
and recommendations relating to surveillance of antibiotic resistance and usage.
Antimicrobial Resistance Summit (2011) Recommendations to contain antimicrobial resistance and usage, and priorities for a 
coordinated an interdisciplinary action plan.
Senate inquiry into the implementation of JETACAR (2013)18 Recommendations to re-establish an independent national management program for 
antimicrobial resistance. 
National Antimicrobial Utilisation Surveillance Program (NAUSP) Monitoring antimicrobial usage data in major hospitals.
Australian Group on Antimicrobial Resistance (AGAR) Prevalence data on important AMR pathogens in Australian hospitals and the 
community.
National Neisseria Network (NNN) Resistance trends in Neisseria gonorrhoeae and Neisseria meningitides.
The Sentry antimicrobial surveillance program Monitors predominant pathogens and resistance patterns for both community-acquired 
and nosocomial infections globally.
The Surveillance Network (TSN) Surveillance database of strain-specific AMR test results daily from participating clinical 
laboratories.
Regulatory
Antimicrobial Resistance Standing Committee  (AMRSC) (2012) Recommendations to contain antimicrobial resistance and usage, and priorities 
for a coordinated an interdisciplinary action plan. Provide scientific and clinical 
expertise informing recommendations for national strategies and priorities to minimise 
antimicrobial resistance. Focus restricted to human health.
The Australian Antimicrobial Resistance Prevention and Containment 
(AMRPC) Steering Group (2013)
Governance to develop and implement an integrated national antimicrobial resistance 
containment framework. 
National Antimicrobial Resistance (AMR) Prevention and Containment 
Strategy announced (Budget 2013-14 Portfolio Budget Statement, DoHA)
Recommendations to re-establish an independent national management program for 
antimicrobial resistance. 
Therapeutic Goods Administration (TGA) ‘Resistant risk assessments’ for new antibiotics (or extensions for indications of existing 
antibacterials). Revised scheduling of all antibacterials for human use as ‘prescription 
only’ (S4).
Pharmaceutical Benefits Scheme (PBS) Advise EAGAR on the listing and level of access to new antibacterials.
Australian Pesticides and Veterinary Medicines Authority (APVMA) Prevention of the registration of fluoroquinolones for use in food producing animals.19
Infection prevention and control
Healthcare Associated Infection Program, Australian Commission on 
Safety and Quality in Healthcare 
National coordination of several initiatives in public and private health care sectors to 
reduce HAI.
NPS MedicineWise National consumer awareness and education campaign. Decision support tools (and 
Shared Decision Making as a core prescribing competency) for uncomplicated ARIs.
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